Under the terms of the agreement, Leios Therapeutics has granted BNC Korea the rights to develop and commercialize 10XB-101 in the following territories; South Korea, Taiwan, Singapore, Indonesia, ...
Reduction of submental fat Patients achieved statistically significant reduction in submental fat thickness as measured from baseline vs. placebo based on MRI (p<0.05 and p<0.001, week 16 and 32, ...
Deoxycholic acid, an endogenously produced bile acid, has emerged as a pioneering non‐surgical treatment for reducing submental fat. By selectively inducing adipocytolysis—the breakdown of fat ...
REROVOT, Israel, March 3, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 ...
Please provide your email address to receive an email when new articles are posted on . An injectable drug for submental body contouring, 10XB101, is now in a phase 2b study. The study’s lead author ...
Cutia Therapeutics (HK:2487) has released an update. Cutia Therapeutics has announced the completion of a Phase II clinical trial for CU-20401, a novel drug targeting submental fat reduction. This ...
Please provide your email address to receive an email when new articles are posted on . After 12 weeks of application, overall skin firmness improved by 61% from baseline. Skin texture improved by 59% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results